Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $7.08 Consensus PT from Analysts

Key Points

• Xeris Biopharma Holdings, Inc. has received a consensus recommendation of "Moderate Buy" from six research firms, with five analysts suggesting a buy and one a hold.
• The average 12-month price target for Xeris Biopharma shares is $7.08, with recent upgrades from analysts raising target prices up to $10.00.
• The company's last earnings report showed a revenue of $67.71 million for the quarter, exceeding the consensus estimate of $64.58 million.

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have been given an average rating of "Moderate Buy" by the six research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $7.0833.

Several equities research analysts have commented on XERS shares. Wall Street Zen lowered Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. HC Wainwright initiated coverage on Xeris Biopharma in a report on Tuesday, August 12th. They set a "buy" rating and a $10.00 target price on the stock. Finally, Leerink Partners boosted their target price on Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a report on Tuesday, August 19th.

Insider Buying and Selling

In other news, Director Marla Persky sold 15,500 shares of the business's stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $7.72, for a total transaction of $119,660.00. Following the transaction, the director directly owned 142,000 shares in the company, valued at $1,096,240. The trade was a 9.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jeffrey W. Sherman sold 42,232 shares of the business's stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $7.92, for a total value of $334,477.44. Following the transaction, the director owned 219,188 shares in the company, valued at approximately $1,735,968.96. This represents a 16.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 207,732 shares of company stock valued at $1,550,437. 6.47% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Apella Capital LLC acquired a new position in Xeris Biopharma in the first quarter valued at approximately $55,000. Xponance Inc. acquired a new position in Xeris Biopharma in the first quarter valued at approximately $57,000. FORA Capital LLC acquired a new position in Xeris Biopharma in the first quarter valued at approximately $60,000. FNY Investment Advisers LLC acquired a new position in Xeris Biopharma in the first quarter valued at approximately $63,000. Finally, Raymond James Financial Inc. acquired a new position in Xeris Biopharma in the fourth quarter valued at approximately $45,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Xeris Biopharma Trading Down 1.7%

NASDAQ:XERS traded down $0.13 during trading hours on Thursday, hitting $7.36. 1,494,603 shares of the stock were exchanged, compared to its average volume of 1,831,488. Xeris Biopharma has a 52-week low of $2.69 and a 52-week high of $8.03. The firm's fifty day moving average price is $6.54 and its 200 day moving average price is $5.32. The company has a market cap of $1.19 billion, a P/E ratio of -35.05 and a beta of 0.13.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02. The firm had revenue of $67.71 million for the quarter, compared to analysts' expectations of $64.58 million. Equities analysts expect that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.